Trial reportNeurology2016
Chronic kidney disease, cerebral blood flow, and white matter volume in hypertensive adults.
Trial report in Neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 64 citations in OpenAlex.
- APOL1 renal-risk variants associate with reduced cerebral white matter lesion volume and increased gray matter volume.Kidney international · 2016Pooled it
- Cerebral small vessel disease and effects of intensive versus standard blood pressure treatment on cardiovascular outcomes and adverse events.Journal of hypertension · 2025Trial
- Intensive Blood Pressure Management Preserves Functional Connectivity in Patients with Hypertension from the Systolic Blood Pressure Intervention Randomized Trial.AJNR. American journal of neuroradiology · 2023Trial
- Kidney Disease, Hypertension Treatment, and Cerebral Perfusion and Structure.American journal of kidney diseases : the official journal of the National Kidney Foundation · 2022Trial
- Changes in brain functional connectivity and cognition related to white matter lesion burden in hypertensive patients from SPRINT.Neuroradiology · 2021Trial
- Long Term Effect of Intensive Lifestyle Intervention on Cerebral Blood Flow.Journal of the American Geriatrics Society · 2018Trial
- Cognitive Function and Kidney Disease: Baseline Data From the Systolic Blood Pressure Intervention Trial (SPRINT).American journal of kidney diseases : the official journal of the National Kidney Foundation · 2017Trial
- The Kidney-Brain Axis in Chronic Kidney Disease: Uremic Toxins, Cognitive Decline, Mechanistic Pathways, Biomarkers and Therapeutic Perspectives.Biomedicines · 2026Review
- Cognitive Function Has an Inverse Association With Cerebral Blood Flow in Individuals With CKD.Kidney medicine · 2026Article
- Observational
- Cerebral Blood Flow and Cognition in CKD: A Physiological Paradox.Journal of the American Society of Nephrology : JASN · 2025Article
- Increased risk of recurrent stroke in patients with impaired kidney function: results of a pooled analysis of individual patient data from the MICON international collaboration.Journal of neurology, neurosurgery, and psychiatry · 2025Article
- Drivers and mechanisms of cognitive decline in chronic kidney disease.Nature reviews. Nephrology · 2025Review
- Cerebral Haemodynamics and Cognitive Impairment in Chronic Haemodialysis Patients: A Pilot Study.Journal of clinical medicine · 2025Article
- Article
- Association between Serum GDF-15 and Cognitive Dysfunction in Hemodialysis Patients.Biomedicines · 2024Article
- Association of Kidney Function With Dementia and Structural Brain Differences: A Large Population-Based Cohort Study.The journals of gerontology. Series A, Biological sciences and medical sciences · 2024Article
- Understanding the impact of pediatric kidney transplantation on cognition: A review of the literature.Pediatric transplantation · 2023Review
- Epidemiology and Risk Factors for Stroke in Chronic Kidney Disease: A Narrative Review.Biomedicines · 2023Review
- Reduced kidney function is associated with poorer domain-specific cognitive performance in community-dwelling older adults.International journal of geriatric psychiatry · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
objectiveTo determine the relation between markers of kidney disease-estimated glomerular filtration rate (eGFR) and urine albumin to creatinine ratio (UACR)-with cerebral blood flow (CBF) and white matter volume (WMV) in hypertensive adults.
methodsWe used baseline data collected from 665 nondiabetic hypertensive adults aged ≥50 years participating in the Systolic Blood Pressure Intervention Trial (SPRINT). We used arterial spin labeling to measure CBF and structural 3T images to segment tissue into normal and abnormal WMV. We used quantile regression to estimate the association between eGFR and UACR with CBF and abnormal WMV, adjusting for sociodemographic and clinical characteristics.
resultsThere were 218 participants (33%) with eGFR <60 mL/min/1.73 m(2) and 146 participants (22%) with UACR ≥30 mg/g. Reduced eGFR was independently associated with higher adjusted median CBF, but not with abnormal WMV. Conversely, in adjusted analyses, there was a linear independent association between UACR and larger abnormal WMV, but not with CBF. Compared to participants with neither marker of CKD (eGFR ≥60 mL/min/1.73 m(2) and UACR <30 mg/g), median CBF was 5.03 mL/100 g/min higher (95% confidence interval [CI] 0.78, 9.29) and abnormal WMV was 0.63 cm(3) larger (95% CI 0.08, 1.17) among participants with both markers of CKD (eGFR <60 mL/min/1.73 m(2) and UACR ≥30 mg/g).
conclusionsAmong nondiabetic hypertensive adults, reduced eGFR was associated with higher CBF and higher UACR was associated with larger abnormal WMV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.